Name: 글로벌 시장 동향
SKU: CD7733
Availability: InStock

보고서 요약(국문)

개요
글로벌 HIV 신속 진단 키트 시장은 2022년 XX억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) XX%로 성장하여 2030년에는 XX억 달러에 이를 것으로 예상됩니다.
신속 HIV 검사는 일반적으로 30분 이내에 HIV 감염 여부를 신속하게 확인할 수 있는 검사입니다. 혈액이나 소변과 같은 체액에서 항체를 검출하는 간단한 검사입니다. HIV 검사는 오랜 시간이 걸리는 채혈 검사에서 30분 이내에 결과를 확인할 수 있는 신속 항원 검사로 획기적으로 변화했습니다.
이 검사는 바이러스 분자에 존재하는 항원에 따라 HIV 1형 또는 2형을 판별합니다. 이를 감별 진단이라고 합니다. 신속 검사는 결과가 더 빨리 나오지만 정확도는 기존 검사보다 높습니다.
주요 동향
HIV 관련 사례 증가
전 세계적으로 HIV 감염률은 높고 매우 빠른 속도로 증가하고 있습니다. 예를 들어, 세계보건기구(WHO)에 따르면 2022년 전 세계 HIV 감염률은 매우 높아 3,900만 명이 HIV에 감염된 채 살아가고 있습니다. 같은 해 약 63만 명이 HIV 관련 질병으로 사망했습니다. HIV 감염자 중 여성은 2,000만 명, 남성은 1,740만 명, 아동은 150만 명으로 가장 많았습니다. 아프리카 지역은 가장 심각한 영향을 받는 지역으로, 성인 25명 중 거의 1명이 HIV에 감염되어 있으며, 이는 전 세계 HIV 감염자의 3분의 2 이상을 차지합니다.
세계 데이터 기관(World in Data Organization)에 따르면 2023년 전 세계 사망자의 1.5% 이상이 HIV로 인해 발생했으며, 아프리카와 같은 저소득 국가에서는 질병 진단 및 치료 접근성이 부족하여 그 비율이 더 높습니다.
또한 유니세프(UNICEF)에 따르면 2000년 기준 18세 미만 아동 14명 이상이 HIV 및 기타 에이즈 관련 원인으로 부모 중 한 명 또는 두 명 모두를 잃었습니다. HIV와 같은 치명적인 질병에 대한 진단 및 치료 옵션이 제한적인 저소득 국가 지역에서는 전염병이 흔히 발생합니다.
신속 검사 결과의 부정확성
현장 검사는 위음성 및 위양성 결과율이 높습니다. 결과가 신속하게 나오기 때문에 민감도는 높지만, 검사 결과가 정확하더라도 위양성 및 위음성 결과가 발생할 수 있으며 이는 심각한 합병증으로 이어질 수 있습니다. 미국 국립보건원(NIH)에 따르면 2023년 신속 검사 키트를 사용한 HIV 오진율은 약 3.1%이며, 위양성 및 위음성 결과는 약 0.4%입니다. 정확도를 위해 신속 검사 후에는 항상 표준 HIV 검사를 시행해야 합니다.
세분화 분석
전 세계 HIV 신속 검사 키트는 기술, 검체, 질병 유형, 유통 채널 및 지역별로 세분화됩니다.
효소면역측정법(ELISA) 부문은 시장 점유율의 약 45.3%를 차지했습니다.
신속 효소면역측정법은 HIV 선별 검사에 가장 일반적으로 사용되는 방법입니다. 효소면역측정법(EIA)은 신속하고 간편하게 HIV 감염 여부를 확인할 수 있습니다. 검사 결과는 사용 후 30분 이내에 나오므로 민감도, 신속성, 정확도가 뛰어나 가정 환경에서도 사용하기에 적합합니다. 혈청 내 항체를 검출하여 정확한 결과를 제공하기 때문에 미국 식품의약국(FDA)의 승인을 받았습니다. 소형 키트 형태로 제공되어 휴대가 간편합니다. HIV 신속 진단 키트의 출시 증가는 시장 수요 증가에 따른 것입니다.
예를 들어, 2023년 2월 Mylab은 HIV 및 간염, 매독과 같은 기타 성병을 검출하는 새로운 신속 진단 키트를 출시했습니다.
2022년 2월 태국 적십자사는 HIV 진단을 위한 신속 자가 진단 키트를 출시했습니다. 이러한 키트는 HIV 진단 및 치료에 대한 사회적 낙인을 해소하기 위해 개발되었습니다.

지리적 분석
북미는 2022년 시장 점유율의 약 42.7%를 차지했습니다.
미국과 캐나다의 높은 HIV 감염률로 인해 북미는 앞으로도 시장에서 가장 큰 비중을 차지할 것으로 예상됩니다.
미국 보건복지부(2023년)에 따르면, 미국에서는 약 120만 명이 HIV에 감염되어 있으며, 이 중 약 13%는 진단받지 못하고 치료도 받지 못하고 있습니다. 2021년 미국에서는 약 32,100명의 신규 HIV 감염자가 발생했으며, 이는 인구 10만 명당 11.5명꼴입니다.
옥스퍼드 학술지(2023년)에 따르면, 2023년 3월 캐나다에서는 15~29세 연령층이 신규 HIV 감염자의 4분의 1 이상을 차지했습니다.
코로나19 영향 분석
코로나19는 코로나19 치료에 대한 관심 증가로 인해 HIV 신속 검사 시장에 영향을 미쳤습니다. 관심의 전환으로 HIV 진단 및 치료가 감소했습니다. 여러 병원에서는 팬데믹 절정기에 환자 방문이 줄었습니다. 신속 HIV 자가 검사 키트에 대한 수요가 감소하고 코로나19 치료로 옮겨갔습니다.
팬데믹 기간 동안 확진자 수가 급증하면서 HIV, 암 등과 같은 치명적인 질병의 진단이 연기되었습니다. HIV 연구 개발이 중단되어 진단 키트 개발에 차질이 생겼습니다. 그러나 코로나19 감염이 통제된 후 종양학 및 감염병과 같은 분야에 대한 관심이 다시 높아졌습니다.

기술별
• 측면 유동 면역 분석법
• 면역 여과법
검체별
• 혈액
• 소변
• 구강액
질병 유형별
• HIV 1형
• HIV 2형
유통 채널별
• 병원 약국
• 일반 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
• 2022년 11월, 애보트는 20분 이내에 결과를 확인할 수 있는 새로운 HIV 자가 검사 키트인 Panbio HIV Self-Test를 출시했습니다. 이 키트는 일반 의약품으로 판매됩니다.

• 2023년 3월, 에모리 대학교는 HIV에 대한 인식을 높이기 위해 전국에 100만 개의 신속 HIV 자가 검사 키트를 배포하는 프로그램을 시작했습니다.
경쟁 환경
HIV 신속 검사 키트 시장의 주요 글로벌 업체로는 Biolytical Laboratories, Meril Life Sciences Pvt. Ltd., JOYSBIO (Tianjin) Biotechnology Co., Ltd, Alpine Biomedicals Pvt Ltd., Abbott Laboratories, Sedia Biosciences Corporation, Trivitron Healthcare, XIAMEN BOSON BIOTECH CO., LTD, F. Hoffmann-La Roche Ltd, Viatris Inc. 등이 있습니다.
보고서 구매 이유
• 기술, 검체, 질병 유형, 유통 채널 및 지역별 글로벌 HIV 신속 검사 키트 시장을 시각화하고 주요 사업 자산 및 업체를 파악하기 위해

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별할 수 있습니다.

• 모든 세그먼트를 포함한 HIV 신속 검사 키트 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트 제공

• PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 자료로 구성됩니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 엑셀 파일로 제공됩니다.
글로벌 HIV 신속 진단 키트 시장 보고서는 약 65개의 표, 65개의 그림, 그리고 195페이지 분량으로 구성됩니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global HIV Rapid Test Kits Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.
A rapid HIV test is useful for the detection of HIV at a faster rate usually in less than 30 minutes. It is a simple test to determine the antibodies in the oral fluids like blood and urine. HIV testing took a drastic shift from normal testing by drawing blood which takes a lot of time to rapid antigen testing which takes less than 30 minutes.
The test determines the type 1 HIV or type 2 which is dependent on the antigen present on the virus molecule. This is called differential detection. Although the results are faster, the accuracy of the standard tests is higher than the rapid ones.
Dynamics
Rising prevalence of HIV-related cases
The worldwide incidence of HIV is high and is increasing at a very fast pace. For instance, according to the World Health Organization, the prevalence of HIV worldwide is very high with 39 million people living with it in 2022. Approximately 6,30,000 people die due to HIV-related illness in 2022. Women who are living with HIV are more with 20 million cases, men with 17.4 million, and children with 1.5 million cases in 2022. African regions are the most severely affected region with nearly 1 in every 25 adults living with HIV which accounts for more than two-thirds of the people living with HIV worldwide.
According to our World in Data Organization, 2023, over 1.5 % of deaths are caused by HIV globally which is more in lower-income countries like Africa due to the unavailability of disease diagnosis and treatment.
Furthermore, according to the UNICEF organization, as of 200 more than 14 children under the age of 18 lost one or both parents due to HIV and other AIDS-related causes. The epidemics are common in low-income country regions due to limitations in the diagnosis and treatment options for deadly diseases like HIV.
Inaccuracy of rapid test results
Point-of-care tests have a high rate of false negative and false positive results. As the results are produced within no time, there is high sensitivity. Although the test results are accurate, false positives and false negatives are possible which can lead to severe complications. According to the National Institute of Health, 2023, misdiagnosis of HIV using rapid test kits is prevalent by about 3.1% and false positive and false negative results are about 0.4%. The rapid test should be always followed by a standard HIV test due to its accuracy.
Segment Analysis
The global HIV rapid test kits are segmented based on technology, specimen, disease Type, distribution channel and region.
The lateral immuno assay Segment Accounted for Approximately 45.3% of the Market Share
Rapid enzyme immunoassays are the most commonly used for HIV screening tests. These enzyme immunoassays are rapid and can be used easily for the detection of HIV infection. The result is out quickly, within 30 minutes of usage which makes it more sensitive, rapid, and accurate and it can be easily used in home care settings. It detects the antibodies in the serum and provides accurate results hence, approved by the FDA. These are available in the form of small kits which makes them handy and portable. The launch of HIV rapid test kits increased due to the demand for these kits in the market.
For instance, in February 2023, Mylab launched new rapid test kits for the detection of HIV and other sexually transmitted diseases like hepatitis and syphilis.
In February 2022, the Thai Red Cross launched rapid-acting self-test kits to detect HIV. These kits are designed to combat social stigma around the diagnosis of HIV and its treatment.
Geographical Analysis
North America accounted for Approximately 42.7% of the Market Share in 2022
North America is expected to hold the largest share of the market due to the high incidence of HIV infections in the US and Canada.
According to the U.S. Department of Health & Human Services, 2023, nearly 1.2 million people in the U.S. are suffering from HIV infection. About 13% are undiagnosed and left untreated. In 2021, there were 32,100 estimated new HIV infections in the U.S. and the rate was 11.5 (per 100,000 people).
In March 2023, according to the Oxford Academic Journal, 2023, individuals with 15-29 account for more than 1 quarter of new HIV cases in Canada.
COVID-19 Impact Analysis
COVID-19 impacted the HIV rapid test market due to an increase in the focus on COVID-19 treatment. The shift in the focus has decreased the diagnosis followed by the treatment of HIV. Several hospitals have seen a decrease in patient visits during the peak of the pandemic. The demand for rapid HIV self-tests decreased and shifted toward the covid 19 treatment.
Due to the rise in cases during the midst of the pandemic, there is the postponement of the diagnosis of deadly diseases like HIV, cancer, etc. The research and development on HIV halted, which impacted the advancements of test kits. However, after the COVID-19 infection came under control, rise in the focus on sectors like oncology and infectious diseases increased.
By Technology
• Lateral Flow Immunoassay
• Immunofiltration
By Specimen
• Blood
• Urine
• Oral Fluid
By Disease Type
• HIV Type 1
• HIV Type 2
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In November 2022, Abbott launched new HIV home test kit, Panbio HIV Self-Test which is available over the counter which show the results within 20 minutes.
• In March 2023, Emory University launched a program to deliver 1 million rapid HIV self-tests across the country to raise awareness about HIV among people.
Competitive Landscape
The major global players in the HIV rapid test kits market include Biolytical Laboratories, Meril Life Sciences Pvt. Ltd., JOYSBIO (Tianjin) Biotechnology Co., Ltd, Alpine Biomedicals Pvt Ltd., Abbott Laboratories, Sedia Biosciences Corporation., Trivitron Healthcare, XIAMEN BOSON BIOTECH CO., LTD, F. Hoffmann-La Roche Ltd, and Viatris Inc. among others.
Why Purchase the Report?
To visualize the global HIV rapid test kits market based on technology, specimen, disease type, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of HIV rapid test kits market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global HIV rapid test kits market report would provide approximately 65 tables, 65 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Technology
3.2. Snippet by Specimen
3.3. Snippet by Disease Type
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising prevalence of HIV-related cases
4.1.2. Increasing incidence of autoimmune diseases
4.1.3. Restraints
4.1.3.1. Inaccuracy of rapid test results
4.1.4. Opportunity
4.1.5. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Epidemiology Statistics
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Technology
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
7.1.2. Market Attractiveness Index, By Technology
7.2. Lateral Flow Immunoassay*
7.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
7.2.2. Market Attractiveness Index, By Technology
7.3. Immunofiltration
8. By Specimen
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
8.1.2. Market Attractiveness Index, By Specimen
8.2. Blood
8.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
8.2.2. Market Attractiveness Index, By Specimen
8.3. Urine
8.4. Oral Fluid
9. By Disease Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.1.2. Market Attractiveness Index, By Disease Type
9.2. HIV Type 1
9.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.2.2. Market Attractiveness Index, By Disease Type
9.3. HIV Type 2
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Russia
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Biolytical Laboratories
13.1.1. Company Overview
13.1.2. Technology Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Meril Life Sciences Pvt. Ltd.
13.3. JOYSBIO (Tianjin) Biotechnology Co., Ltd
13.4. Alpine Biomedicals Pvt Ltd.
13.5. Abbott Laboratories
13.6. Sedia Biosciences Corporation.
13.7. Trivitron Healthcare
13.8. XIAMEN BOSON BIOTECH CO., LTD
13.9. F. Hoffmann-La Roche Ltd
13.10. Viatris Inc.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Biolytical Laboratories, 4.	Key Developments, Meril Life Sciences Pvt. Ltd., JOYSBIO (Tianjin) Biotechnology Co., Ltd, Alpine Biomedicals Pvt Ltd., Abbott Laboratories, Sedia Biosciences Corporation., Trivitron Healthcare, XIAMEN BOSON BIOTECH CO., LTD, F. Hoffmann-La Roche Ltd, Viatris Inc.

표 목록 (Tables)

List of Tables

Table 1 Global HIV Rapid Test Kits Market Value, By Technology, 2022, 2026 & 2030 (US$ Million)

Table 2 Global HIV Rapid Test Kits Market Value, By Specimen, 2022, 2026 & 2030 (US$ Million)

Table 3 Global HIV Rapid Test Kits Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 4 Global HIV Rapid Test Kits Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 5 Global HIV Rapid Test Kits Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global HIV Rapid Test Kits Market Value, By Technology, 2021-2030 (US$ Million)

Table 7 Global HIV Rapid Test Kits Market Value, By Specimen, 2021-2030 (US$ Million)

Table 8 Global HIV Rapid Test Kits Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 9 Global HIV Rapid Test Kits Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 10 Global HIV Rapid Test Kits Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 11 Global HIV Rapid Test Kits Market Value, By Region, 2021-2030 (US$ Million)

Table 12 North America HIV Rapid Test Kits Market Value, By Technology, 2021-2030 (US$ Million)

Table 13 North America HIV Rapid Test Kits Market Value, By Specimen, 2021-2030 (US$ Million)

Table 14 North America HIV Rapid Test Kits Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 15 North America HIV Rapid Test Kits Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 16 North America HIV Rapid Test Kits Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America HIV Rapid Test Kits Market Value, By Technology, 2021-2030 (US$ Million)

Table 18 South America HIV Rapid Test Kits Market Value, By Specimen, 2021-2030 (US$ Million)

Table 19 South America HIV Rapid Test Kits Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 20 South America HIV Rapid Test Kits Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 21 South America HIV Rapid Test Kits Market Value, By Country, 2021-2030 (US$ Million)

Table 22 Europe HIV Rapid Test Kits Market Value, By Technology, 2021-2030 (US$ Million)

Table 23 Europe HIV Rapid Test Kits Market Value, By Specimen, 2021-2030 (US$ Million)

Table 24 Europe HIV Rapid Test Kits Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 25 Europe HIV Rapid Test Kits Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 26 Europe HIV Rapid Test Kits Market Value, By Country, 2021-2030 (US$ Million)

Table 27 Asia-Pacific HIV Rapid Test Kits Market Value, By Technology, 2021-2030 (US$ Million)

Table 28 Asia-Pacific HIV Rapid Test Kits Market Value, By Specimen, 2021-2030 (US$ Million)

Table 29 Asia-Pacific HIV Rapid Test Kits Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 30 Asia-Pacific HIV Rapid Test Kits Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 31 Asia-Pacific HIV Rapid Test Kits Market Value, By Country, 2021-2030 (US$ Million)

Table 32 Middle East & Africa HIV Rapid Test Kits Market Value, By Technology, 2021-2030 (US$ Million)

Table 33 Middle East & Africa HIV Rapid Test Kits Market Value, By Specimen, 2021-2030 (US$ Million)

Table 34 Middle East & Africa HIV Rapid Test Kits Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 35 Middle East & Africa HIV Rapid Test Kits Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 36 Biolytical Laboratories: Overview

Table 37 Biolytical Laboratories: Product Portfolio

Table 38 Biolytical Laboratories: Key Developments

Table 39 Meril Life Sciences Pvt. Ltd.: Overview

Table 40 Meril Life Sciences Pvt. Ltd.: Product Portfolio

Table 41 Meril Life Sciences Pvt. Ltd.: Key Developments

Table 42 JOYSBIO (Tianjin) Biotechnology Co., Ltd : Overview

Table 43 JOYSBIO (Tianjin) Biotechnology Co., Ltd : Product Portfolio

Table 44 JOYSBIO (Tianjin) Biotechnology Co., Ltd : Key Developments

Table 45 Alpine Biomedicals Pvt Ltd.: Overview

Table 46 Alpine Biomedicals Pvt Ltd.: Product Portfolio

Table 47 Alpine Biomedicals Pvt Ltd.: Key Developments

Table 48 Abbott Laboratories: Overview

Table 49 Abbott Laboratories: Product Portfolio

Table 50 Abbott Laboratories: Key Developments

Table 51 Sedia Biosciences Corporation.: Overview

Table 52 Sedia Biosciences Corporation.: Product Portfolio

Table 53 Sedia Biosciences Corporation.: Key Developments

Table 54 Trivitron Healthcare: Overview

Table 55 Trivitron Healthcare: Product Portfolio

Table 56 Trivitron Healthcare: Key Developments

Table 57 XIAMEN BOSON BIOTECH CO., LTD: Overview

Table 58 XIAMEN BOSON BIOTECH CO., LTD: Product Portfolio

Table 59 XIAMEN BOSON BIOTECH CO., LTD: Key Developments

Table 60 F. Hoffmann-La Roche Ltd: Overview

Table 61 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 62 F. Hoffmann-La Roche Ltd: Key Developments

Table 63 Viatris Inc.: Overview

Table 64 Viatris Inc.: Product Portfolio

Table 65 Viatris Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 2 Global HIV Rapid Test Kits Market Share, By Technology, 2022 & 2030 (%)

Figure 3 Global HIV Rapid Test Kits Market Share, By Specimen, 2022 & 2030 (%)

Figure 4 Global HIV Rapid Test Kits Market Share, By Disease Type, 2022 & 2030 (%)

Figure 5 Global HIV Rapid Test Kits Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global HIV Rapid Test Kits Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global HIV Rapid Test Kits Market Y-o-Y Growth, By Technology, 2022-2030 (%)

Figure 8 Lateral Flow Immunoassay HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 9 Immunofiltration HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 10 Global HIV Rapid Test Kits Market Y-o-Y Growth, By Specimen, 2022-2030 (%)

Figure 11 Blood Specimen in Global HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 12 Urine Specimen in Global HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 13 Oral Fluid Specimen in Global HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 14 Global HIV Rapid Test Kits Market Y-o-Y Growth, By Disease Type, 2022-2030 (%)

Figure 15 HIV Type 1 Disease Type in Global HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 16 HIV Type 2 Disease Type in Global HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 17 Global HIV Rapid Test Kits Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 18 Hospital Pharmacies in Global HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 19 Retail Pharmacies in Global HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 20 Online Pharmacies in Global HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 21 Global HIV Rapid Test Kits Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 22 North America HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 23 Asia-Pacific HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 24 Europe HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 25 South America HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 26 Middle East and Africa HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 27 North America HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 28 North America HIV Rapid Test Kits Market Share, By Technology, 2022 & 2030 (%)

Figure 29 North America HIV Rapid Test Kits Market Share, By Specimen, 2022 & 2030 (%)

Figure 30 North America HIV Rapid Test Kits Market Share, By Disease Type, 2022 & 2030 (%)

Figure 31 North America HIV Rapid Test Kits Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 32 North America HIV Rapid Test Kits Market Share, By Country, 2022 & 2030 (%)

Figure 33 South America HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 34 South America HIV Rapid Test Kits Market Share, By Technology, 2022 & 2030 (%)

Figure 35 South America HIV Rapid Test Kits Market Share, By Specimen, 2022 & 2030 (%)

Figure 36 South America HIV Rapid Test Kits Market Share, By Disease Type, 2022 & 2030 (%)

Figure 37 South America HIV Rapid Test Kits Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 38 South America HIV Rapid Test Kits Market Share, By Country, 2022 & 2030 (%)

Figure 39 Europe HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 40 Europe HIV Rapid Test Kits Market Share, By Technology, 2022 & 2030 (%)

Figure 41 Europe HIV Rapid Test Kits Market Share, By Specimen, 2022 & 2030 (%)

Figure 42 Europe HIV Rapid Test Kits Market Share, By Disease Type, 2022 & 2030 (%)

Figure 43 Europe HIV Rapid Test Kits Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 44 Europe HIV Rapid Test Kits Market Share, By Country, 2022 & 2030 (%)

Figure 45 Asia-Pacific HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 46 Asia-Pacific HIV Rapid Test Kits Market Share, By Technology, 2022 & 2030 (%)

Figure 47 Asia-Pacific HIV Rapid Test Kits Market Share, By Specimen, 2022 & 2030 (%)

Figure 48 Asia-Pacific HIV Rapid Test Kits Market Share, By Disease Type, 2022 & 2030 (%)

Figure 49 Asia-Pacific HIV Rapid Test Kits Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 50 Asia-Pacific HIV Rapid Test Kits Market Share, By Country, 2022 & 2030 (%)

Figure 51 Middle East & Africa HIV Rapid Test Kits Market Value, 2021-2030 (US$ Million)

Figure 52 Middle East & Africa HIV Rapid Test Kits Market Share, By Technology, 2022 & 2030 (%)

Figure 53 Middle East & Africa HIV Rapid Test Kits Market Share, By Specimen, 2022 & 2030 (%)

Figure 54 Middle East & Africa HIV Rapid Test Kits Market Share, By Disease Type, 2022 & 2030 (%)

Figure 55 Middle East & Africa HIV Rapid Test Kits Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 56 Biolytical Laboratories: Financials

Figure 57 Meril Life Sciences Pvt. Ltd.: Financials

Figure 58 JOYSBIO (Tianjin) Biotechnology Co., Ltd: Financials

Figure 59 Alpine Biomedicals Pvt Ltd.: Financials

Figure 60 Abbott Laboratories: Financials

Figure 61 Sedia Biosciences Corporation.: Financials

Figure 62 Trivitron Healthcare: Financials

Figure 63 XIAMEN BOSON BIOTECH CO., LTD: Financials

Figure 64 F. Hoffmann-La Roche Ltd: Financials

Figure 65 Viatris Inc.: Financials

글로벌 HIV 신속 진단 키트 시장 – 2023-2030

Global HIV Rapid Test Kits Market - 2023-2030